Biotech News

Neurocrine Biosciences to Present at the 2026 Jefferies Global Healthcare Conference

Neurocrine Biosciences (NBIX)Neurocrine BiosciencesConference / presentation

SAN DIEGO, Nov. 10, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that its executives will participate at the 2026 Jefferies Global Healthcare Conference in London at 3:30 p.m. Greenwich Mean Time ( 10:30 a.m. Eastern Time) on November 17, 2026.

Related news

NBIXNeurocrine Biosciences2026-09-30 12:30 EST

Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference

TEVATeva Pharmaceutical Industries2026-11-20 21:30 EST

Teva to Present at the 9th Annual Evercore Healthcare Conference, the Piper Sandler 38th Annual Healthcare Conference and Citi’s 2026 Global Healthcare Conference

CGTXCognition Therapeutics2026-11-09 12:30 EST

Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference

TNXPTonix Pharmaceuticals2026-11-04 12:00 EST

Tonix Pharmaceuticals to Present at Guggenheim’s 3rd Annual Healthcare Innovation Conference

NERVMinerva Neuroscience2026-10-29 11:00 EST

Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in London

NBIXNeurocrine Biosciences2026-10-16 12:30 EST

Neurocrine Biosciences Presents Real-World Evidence Mapping the Lifelong, Evolving Impact of Classic Congenital Adrenal Hyperplasia

HRMYHarmony Biosciences2026-10-01 12:05 EST

Harmony Biosciences Announces Poster Presentation at the 17th European Narcolepsy Days

HRMYHarmony Biosciences2026-11-19 13:05 EST

Harmony Biosciences to Participate in Upcoming Investor Conferences

GANXGain Therapeutics2026-09-17 11:00 EST

Gain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference

ALKSAlkermes plc2026-11-03 21:00 EST

Alkermes to Present at Upcoming Investor Conferences

Neurocrine Biosciences

Neuroscience and Endocrinology Portfolio Neurocrine Biosciences discovers, develops and commercializes medicines for neuropsychiatric, neurological, endocrine and immunological disorders. Its business combines several first-in-class commercial products with a deep mid- and late-stage pipeline. Commercial Medicines The portfolio includes...

Recent company news

Stock data

Close
156.59 USD
Market cap
15.57B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States